Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serono researchers have achieved a major milestone in identifying and creating a register of genes involved in multiple sclerosis as part of a project that will form the basis for future therapies.
Subscribe to our email newsletter
For the first time in this disease area, researchers at the Serono Genetics Institute (SGI) have identified 80 genes involved in the inflammatory and neuro-degenerative pathways of multiple sclerosis (MS).
The finding is based on a 40% genome scan comparing the genetic profile of a total of 1,800 people with MS and healthy individuals in different populations.
The understanding of the disease genetics in MS will enhance Serono’s drug discovery in identifying proteins that can be used either as targets for drug development or directly as therapeutics. In addition, the knowledge of genetics in MS provides a basis for better designing safer and more effective drugs and enabling physicians to address unmet needs and potentially better match treatments to the individual patient.
“We are excited about this significant step forward in building a complete inventory of genes involved in MS, ” said Professor Daniel Cohen, vice-president and worldwide head of genetics at Serono. “The completion of the MS whole genome scan in 2006 will lead to a comprehensive catalogue of potential MS drug targets providing a basis for the future development of innovative MS therapies.”